US EditionWHO approves Moleculin’s name for next-gen anthracycline - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
WHO approves Moleculin’s name for next-gen anthracycline - BioTuesdays
Moleculin Biotech (NASDAQ:MBRX) announced that the International Nonproprietary Names (INN) expert committee of the World Health Organization (WHO) has approved “naxtarubicin” as the non-proprietary name of its next-generation anthracycline in development, Annamycin. Annamycin is in development for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and soft tissue sarcoma (STS) lung metastases. According to Moleculin, Annam…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
